Pharmaceutical Executive Daily: Vinay Prasad Set to Leave CBER for Second Time

Summary

Vinay Prasad has left the FDA’s Center for Biologics Evaluation and Research (CBER) for the second time in under a year, signaling a notable leadership turnover at a key regulatory hub for biologics, vaccines and gene therapies. In parallel, GlaxoSmithKline and Alfasigma signed a licensing deal to co‑develop a liver‑disease therapy, and Servier announced a roughly $2 billion acquisition of Day One Biopharmaceuticals, underscoring ongoing consolidation and external innovation in the pharma sector. Additionally, Ipsen withdrew its oncology drug Tazverik from the market after emerging clinical trial data altered the drug’s risk‑benefit profile.